| Literature DB >> 34946766 |
Mohamed El-Sherbiny1,2, Eslam K Fahmy3,4, Nada H Eisa5, Eman Said6,7, Hany A Elkattawy1,3,8, Hasnaa Ali Ebrahim9, Nehal M Elsherbiny5,10, Fatma M Ghoneim11.
Abstract
The development of the field of nanotechnology has revolutionized various aspects in the fields of modern sciences. Nano-medicine is one of the primary fields for the application of nanotechnology techniques. The current study sheds light on the reno-protective impacts of gold nano-particles; nanogold (AuNPs) against 5-flurouracil (5-FU)-induced renal toxicity. Indeed, the use of 5-FU has been associated with kidney injury which greatly curbs its therapeutic application. In the current study, 5-FU injection was associated with a significant escalation in the indices of renal injury, i.e., creatinine and urea. Alongside this, histopathological and ultra-histopathological changes confirmed the onset of renal injury. Both gene and/or protein expression of nuclear factor erythroid 2-related factor 2 (Nrf-2) and downstream antioxidant enzymes revealed consistent paralleled anomalies. AuNPs administration induced a significant renal protection on functional, biochemical, and structural levels. Renal expression of the major sensor of the cellular oxidative status Nrf-2 escalated with a paralleled reduction in the renal expression of the other contributor to this axis, known as Kelch-like ECH-associated protein 1 (Keap-1). On the level of the effector downstream targets, heme oxygenase 1 (HO-1) and gamma-glutamylcysteine synthetase (γ-GCS) AuNPs significantly restored their gene and protein expression. Additionally, combination of AuNPs with 5-FU showed better cytotoxic effect on MCF-7 cells compared to monotreatments. Thus, it can be inferred that AuNPs conferred reno-protective impact against 5-FU with an evident modulatory impact on Nrf-2/Keap-1 and its downstream effectors, HO-1 and γ-GCS, suggesting its potential use in 5-FU regimens to improve its therapeutic outcomes and minimize its underlying nephrotoxicity.Entities:
Keywords: 5-flurouracil; Nrf-2; nanogold
Mesh:
Substances:
Year: 2021 PMID: 34946766 PMCID: PMC8707269 DOI: 10.3390/molecules26247684
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Effect of AuNPs treatment on 5-FU-induced renal injury. AuNPs significantly reduced 5-FU-elevated serum creatinine (A) and urea (B) levels (n = 4–6). * p < 0.05, ** p < 0.01 indicate statistical significance compared with the 5-FU group. (C) Representative microscopic images of H&E stained renal sections, showing normal glomeruli (G) and tubules (T) with minimal interstitial tissue in control normal and AuNPs control groups, diffuse severe tubular degeneration (crossed arrows), multifocal tubular necrosis (arrows), glomerular shrinkage (arrowhead), interstitial fibrosis (curved arrows) in the 5-FU group. Mild tubular degeneration (crossed arrows) and great improvement of histology of glomeruli (G) and tubules (T) with minimal interstitial tissue was also shown in the 5-FU+AuNPs group. Low magnification (100×) and high magnification (400×) were used for acquiring images with indicated scale bar. Two different sections (10 fields each) were analyzed (n = 6).
Figure 2Effect of AuNPs treatment on renal cortical ultrastructural changes induced by 5-FU (A–H).
Figure 3Effect of AuNPs treatment on differential expression of Nrf-2/Keap-1 axis. (A) Representative microscopic images of immunohistochemical staining show the reduced expression of the Nrf-2 in the 5-FU group compared with normal and AuNPs control groups (Arrow heads). AuNPs treatment showed significant restoration of Nrf-2 expression in the 5-FU+ AuNPs group compared with the 5-FU group (Arrow heads). High magnification (400×) was used with a scale bar (25 µm). (B) Percentage area of Nrf-2 immunostaining (n = 6). **** p < 0.0001 indicates statistical significance compared with the 5-FU group. (C) Representative microscopic images of immunohistochemical staining showing increased expression of Keap-1 in the 5-FU group compared with normal and AuNPs control groups (Arrow heads). AuNPs treatment showed significant reduction in Keap-1 expression in the 5-FU+AuNPs group compared with the 5-FU group (Arrow heads). High magnification (400×) was used with scale bar indicated (25 µm). (D) Percentage area of Keap-1 immunostaining (n = 6). **** p < 0.0001 indicate statistical significance compared with the 5-FU group.
Figure 4Effect of AuNPs treatment on differential expression of HO-1 and γ-GCS downstream molecules of Nrf-2. (A) Fold change in HO-1 mRNA levels relative to GAPDH, as determined by real time PCR (n = 4). *** p < 0.001, **** p < 0.0001 indicate statistical significance compared with the 5-FU group. (B) Representative microscopic images of immunohistochemical staining showing reduced expression of HO-1 in the 5-FU group compared with normal and AuNPs control groups (Arrow heads). AuNPs treatment showed significant restoration of HO-1 expression in the 5-FU+AuNPs group compared with the 5-FU group (Arrow heads). High magnification (400X) was used with scale bar indicated (25 µm). (C) Percentage area of HO-1 immunostaining (n = 6). * p < 0.05, *** p < 0.001, **** p < 0.0001 indicate statistical significance compared with the 5-FU group. (D) Fold change in γ-GCS mRNA levels relative to GAPDH as determined by real time PCR (n = 4). **** p < 0.0001 indicate statistical significance compared with the 5-FU group. (E) Representative microscopic images of immunohistochemical staining showing reduced expression of γ-GCS in the 5-FU group compared with the normal and AuNPs control groups (Arrow heads). AuNPs treatment showed significant restoration of γ-GCS expression in the 5-FU+AuNPs group compared with the 5-FU group (Arrow heads). High magnification (400×) was used with a scale bar (25 µm). (F) Percentage area of γ-GCS immunostaining (n = 6). **** p < 0.0001 indicate statistical significance compared with the 5-FU group.
Figure 5Effect of 24 treatment with 5-FU (100 µg/mL), AuNPs (10, 25, 25 µg/mL), and their combination on MCF-7 cells viability. Results are presented as mean ± SE. * p < 0.05 compared to 5-FU (100 µg/mL)-treated cells.
Primers’ sequences of all studied genes.
| Gene Symbol | Forward | Reverse | Gene Bank |
|---|---|---|---|
| HO-1 | 5′-GAGCGCCCACAGCTCGACAG-3′ | 5′-GTGGGCCACCAGCAGCTCAG-3′ | XM_032887931.1 |
| γ-GCS | 5′-AGACACGGCATCCTCCAGTT-3′ | 5′-CTGACACGTAGCCTCGGTAA-3′ | NM_012815.2 |
| GAPDH | 5′-ATGGTGAAGGTCGGTGTGAACG-3′ | 5′-TGGTGAAGACGCCAGTAGACTC-3′ | XM_017592435.10 |